Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Greenberg

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Leukemia & Lymphoma|August 22, 2012
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabinePeter L Greenberg, Guillermo Garcia-Manero, Michael Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trialsMichael Zach Koontz, Sandra J Horning, Raymond Balise, et al.
Journal of Hematopathology|February 20, 2026
Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotypeJyoti Kumar, Alexandria Jensen, Rong Lu, et al.
Scientific Reports|November 23, 2013
Specific plasma autoantibody reactivity in myelodysplastic syndromesGeorge I Mias, Rui Chen, Yan Zhang, et al.
Leukemia Research|September 20, 2011
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaMahesh Seetharam, Alice C Fan, Mai Tran, et al.
Blood Advances|June 23, 2020
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasmsMichael A Spinner, Alexey Aleshin, Marianne T Santaguida, et al.
Leukemia Research|December 28, 2023
The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasmsVishesh Khanna, Rong Lu, Jyoti Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2013
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromesWendy W Pang, John V Pluvinage, Elizabeth A Price, et al.
Leukemia & Lymphoma|April 5, 2018
Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cellsHogune Im, Varsha Rao, Kunju Sridhar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2010
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromesPeter L Greenberg, Cynthia K Rigsby, Richard M Stone, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Leukemia & Lymphoma|August 22, 2012
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabinePeter L Greenberg, Guillermo Garcia-Manero, Michael Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trialsMichael Zach Koontz, Sandra J Horning, Raymond Balise, et al.
Journal of Hematopathology|February 20, 2026
Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotypeJyoti Kumar, Alexandria Jensen, Rong Lu, et al.
Scientific Reports|November 23, 2013
Specific plasma autoantibody reactivity in myelodysplastic syndromesGeorge I Mias, Rui Chen, Yan Zhang, et al.
Leukemia Research|September 20, 2011
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaMahesh Seetharam, Alice C Fan, Mai Tran, et al.
Blood Advances|June 23, 2020
Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasmsMichael A Spinner, Alexey Aleshin, Marianne T Santaguida, et al.
Leukemia Research|December 28, 2023
The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasmsVishesh Khanna, Rong Lu, Jyoti Kumar, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2013
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromesWendy W Pang, John V Pluvinage, Elizabeth A Price, et al.
Leukemia & Lymphoma|April 5, 2018
Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cellsHogune Im, Varsha Rao, Kunju Sridhar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2010
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromesPeter L Greenberg, Cynthia K Rigsby, Richard M Stone, et al.
Pageof 10